Anti-CCR8 antibodies and uses thereof

US12258411B2 · kind B2 · utility

Assignees

• AMGEN INC. · US
• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Nathan William Pierce · Mountain View, US
• Agnieszka KIELCZEWSKA · Vancouver, CA
• Wentao Chen · Walnut Creek, US
• Olivier Nolan-Stevaux · Millbrae, US
• Darren L. Bates · Oak Park, US
• Lisa Winkel · Munich, DE
• Christoph Dahlhoff · Munich, DE
• Tobias Raum · Munich, DE
• Claudia Bluemel · Munich, DE
• Jonas Karl-Josef Honer · Munich, DE

Key dates

• Filing date: Jun 2, 2022
• Grant date: Mar 25, 2025
• Expiry date: Jun 2, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.